Raptor Pharmaceutical Announces FDA Acceptance of NDA for RP103 for the Potential Treatment of Nephropathic Cystinosis

By Sam | April 8, 2016

Raptor Pharmaceutical announced that the FDA has accepted for filing its new drug application (NDA) for its investigational drug candidate, cysteamine bitartrate delayed-release capsules (RP103), for the potential treatment of nephropathic cystinosis.

Posted in FDAnews Drug Daily Bulletin